Prostate-specific antigen to predict outcome of external beam radiation for prostate cancer: Walter Reed army medical center experience 1988-1995

Urology

Volumn 53, Issue 1, 1999, Pages 131-138

  Preston, David M ^a,b   Bauer, John J ^a,b   Connelly, Roger R ^b   Sawyer, Timothy ^c   Halligan, John ^c   Leifer, Eric S ^c   McLeod, David G ^a,b   Moul, Judd W ^a,b  

^a Urology Service   (United States)

^b UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^c WALTER REED ARMY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER;

ADULT; AGED; ARTICLE; BEAM THERAPY; CANCER GRADING; CANCER RECURRENCE; CANCER STAGING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HUMAN; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PROSTATE CANCER; STATISTICAL ANALYSIS; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM RECURRENCE, LOCAL; PREDICTIVE VALUE OF TESTS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 0032929496     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(98)00464-6     Document Type: Article

References (33)

1. Partin A.W., Oesterling J.F. The clinical usefulness of prostatic-specific antigen update . J Urol. 152:1994;1358-1368.
2. Partin A.W., Kattan M.W., Subong E.N.P., et al. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer a multi-institutional update . JAMA. 277:1997;1445-1451.
3. Kaplan I.D., Cox R.S., Bagshaw M.A. Prostate specific antigen after external beam radiotherapy for prostate cancer follow-up . J Urol. 149:1993;519-522.
4. Russell K.J., Dunatove C., Hafermann M.D., et al. Prostate specific antigen in the management of patients with localized adenocarcinoma of the prostate treated with primary radiation therapy. J Urol. 146:1991;1046-1052.
5. Zagars G.K., Pollack A., Kavadi V.S., et al. Prostate-specific antigen and radiation therapy for clinically localized prostate cancer. Int J Radiat Oncol Biol Phys. 32:1995;293-306.
6. Hanks G.E., Hanlon A.L., Hudes G., et al. Patterns-of-failure analysis of patients with high pretreatment prostate-specific antigen levels treated by radiation therapy the need for improved systemic and locoregional treatment . J Clin Oncol. 14:1996;1093-1097.
7. Chauvet B., Felix-Faure C., Lupsascka N., et al. Prostate-specific antigen decline a major prognostic factor for prostate cancer treated with radiation therapy . J Clin Oncol. 12:1994;1402-1407.
8. Roach M. III, Krall J., Keller J., et al. The prognostic significance of race and survival from prostate cancer based on patients irradiated on radiation therapy oncology group protocols (1976-1985). Int J Radiat Oncol Biol Phys. 24:1992;441-449.
9. Pollack A., Zagars G.K. External beam radiotherapy for stage T1/T2 prostate cancer how does it stack up? Urology. 51:1998;258-264.
10. Fukunaga-Johnson N., Sandier H.M., McLaughlin P.W., et al. Results of 3D conformal radiotherapy in the treatment of localized cancer. Int J Radiat Oncol Biol Phys. 38:1997;311-317.
11. Critz F.A., Levinson A.K., Williams W.H., et al. Prostate-specific antigen nadir the optimum level after irradiation for prostate cancer . J Clin Oncol. 14:1996;2889-2892.
12. Cox J.D., Gringnon D.J., Kaplan R.S., et al. Consensus statement guidelines for PSA following radiation therapy . Int J Radiat Oncol Biol Phys. 37:1997;1035-1041.
13. Schroeder F.H., Hermanek P., Denis L., et al. The TNM classification of prostate cancer. Prostate Suppl. 4:1992;129.
14. Kaplan E.L., Meier P.M. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 53:1958;457-481.
15. Cox D.R. Regression models and life tables. J R Stat Soc [B]. 34:1972;187-220.
16. Hanks G.E., Lee W.R., Hanlon A.L., et al. Conformal technique dose escalation in prostate cancer improved cancer control with higher doses in patients with pretreatment PSA 10 ng/ml . Int J Radiat Oncol Biol Phys. 32:(suppl):1995;141-142.
17. Zeitman A.L., Dallow K.C., McManus P.A., et al. Time to second prostate specific antigen (PSA) failure is a surrogate endpoint for prostate cancer death in prospective trials of therapy for localized disease. Urology. 47:1996;236-239.
18. Zeitman A.L., Coen J.J., Dallow K.C., et al. The treatment of prostate cancer by conventional radiation therapy an analysis of long-term outcome . Int J Radiat Oncol Biol Phys. 32:1995;287-292.
19. Zagars G.K., Pollack A., Kavadi V.S., et al. Prostate-specific antigen and radiation therapy for clinically localized prostate cancer. Int J Radiat Oncol Biol Phys. 32:1995;293-306.
20. Kuban D.A., El-Mahdi A.M., Schellhammer P.F. Prostate-specific antigen for pretreatment prediction and post-treatment evaluation of outcome after definitive irradiation for prostate cancer. Int J Radiat Oncol Biol Phys. 32:1995;307-316.
21. Zagars G.K., Pollak A., von Eschenbach A.C. Prognostic factors for clinically localized prostate carcinoma analysis of 938 patients irradiated in the prostate specific antigen era . Cancer. 79:1997;1370-1380.
22. Lee R.W., Hanks G.E., Schultheiss T.E., et al. Localized prostate cancer treated by external beam radiotherapy alone serum prostate-specific antigen driven outcome . J Clin Oncol. 13:1995;464-469.
23. Bolla M., Gonzalez D., Warde P., et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med. 337:1997;295-300.
24. Pilepich M.V., Caplan R.W., Byhardt C.A., et al. Phase I11 trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy report of radiation therapy oncology group protocol 8531 . J Clin Oncol. 15:1997;1013-1021.
25. Roach M. III, Lu J., Pilepich M., et al. Long term survival in 1500 men treated for prostate cancer with radiotherapy alone radiation therapy oncology group (RTOG) protocols 7706, 7506, 8531, and 8610 . J Urol. 159:(suppl):1998;219.
26. Kim J.A., Kuban D.A., EI-Mahdi A.M., et al. Carcinoma of the prostate race as a prognostic indicator in definitive radiation therapy . Radiology. 194:1995;545-549.
27. Hanks G.E., Perez C.A., Kozar M., et al. PSA confirmation of cure at 10 years of T1b, T2, N0, M0 prostate cancer patients treated in RTOG protocol 7706 with external beam irradiation. Int J Radiat Oncol Biol Phys. 30:1994;289-292.
28. Kavadi V.S., Zagars G.K., Pollack A. Serum prostate-specific antigen after radiation therapy for clinically localized prostate cancer prognostic implications . Int J Radiat Oncol Biol Phys. 30:1994;279-287.
29. Crook J., Perry G., Robertson S., et al. Radiotherapy for localized prostate cancer assessment of results by systematic biopsy and PSA . Can J Urol. 3:1996;195-201.
30. Critz F.A., Levinson K., Williams W.H., et al. The PSA nadir goal for radiotherapy of prostate cancer is ≤ 0 2 ng/ml . J Urol. 159:(suppl):1998;218.
31. Kabalin J.N., Hodge K.K., McNeal J.E., et al. Identification of residual cancer in the prostate following radiation therapy role of transrectal ultrasound-guided biopsy and prostate-specific antigen . J Urol. 142:1989;326-331.
32. Dugan T.C., Shipley W.U., Young R.H., et al. Biopsy after external beam radiation therapy for adenocarcinoma of the prostate correlation with original histological grade and current prostatic specific antigen levels . J Urol. 146:1991;1313-1316.
33. Keyser D., Kupelian P.A., Zippe C.D., et al. Stage T1-T2 prostate cancer with pretreatment prostate specific antigen level <10 ng/ml radiation therapy or surgery? Int J Radiat Oncol Biol Phys. 38:1997;723-729.